FREMONT, Calif.–(BUSINESS WIRE)–Emboline, Inc. (www.emboline.com), an emerging medical device company, will
debut its game-changing embolic protection devices for percutaneous heart valve
repair and replacement in San
Francisco next week. The Company is initially focused
on developing its novel Emboline CAP™ device; a next-generation system intended
to provide complete protection of the arterial bed (both the cerebrals and the
aortic lumen) utilizing a uniquely ported design that maintains tool access
through the filter. In addition, Emboline is also developing Emboliner™, a
simple-to-use, low profile system for protection of the cerebral vessels alone.
Embolines technologies are derived from intellectual
property invented by Amir Belson, M.D., founder of Neoguide Systems, a company
that developed platform technology for minimally invasive surgical procedures
and was acquired by Intuitive Surgical in 2009.
Emboline is working toward an acute preclinical
proof-of-concept of its technology, targeted by Q1 2012. The proof-of-concept
development is being done in partnership with NDC (Fremont,
Calif.), SeptRx, Inc. (Fremont,
Calif.) and US BioDesign (Perkasie, Penn.).
“The major focus on transcatheter aortic valve replacement
at next weeks TCT 2011 conference in San
Francisco is strong evidence of the important need for
our technology,” said Scott Russell, Embolines General Manager. “For these
exciting new TAVR procedures to reach their true potential, the stroke risk
must be properly managed. Our technology not only eliminates the risk of
embolic stroke from these procedures, but it is also the only technology to
simultaneously shield the aortic lumen to protect the rest of the arterial bed
Cerebral embolism is a known complication of cardiac surgery, cardiopulmonary
bypass and catheter based interventional cardiology and electrophysiology
procedures. Embolic particles, which may include thrombus, atheroma and lipids,
may become dislodged by surgical or catheter manipulations and enter the
bloodstream. Cerebral embolism can lead to neuropsychological deficits, stroke
and even death. Other organs downstream can also be damaged by embolism,
resulting in diminished function or organ failure. Prevention of such embolism
would benefit patients and improve the outcome of these procedures. These risks
are especially critical in transcatheter aortic valve replacement (TAVR).
Stroke rates related to TAVR have been recorded at between four and 20 percent.
During catheter delivery and valve implantation, plaque may be dislodged from
the vasculature and may travel through the carotid circulation and into the
brain. The adoption and growth of TAVR procedures may be stifled until a
reliable, simple-to-use embolic protection system exists to improve the safety
of these procedures.
For further information about Embolines technologies,
please contact Scott Russell (General Manager) at firstname.lastname@example.org,